Halberd Corporation (HALB)
USD 0.0
(-13.64%)
USD 0.0
(-13.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -79.67 Thousand USD | 82.45% |
| 2023 | -454.07 Thousand USD | 72.05% |
| 2022 | -1.62 Million USD | -88.59% |
| 2021 | -861.53 Thousand USD | 47.6% |
| 2020 | -1.64 Million USD | -7402.03% |
| 2019 | -21.91 Thousand USD | -54.05% |
| 2018 | -14.22 Thousand USD | 96.19% |
| 2017 | -373.3 Thousand USD | -6342.49% |
| 2016 | 5980.00 USD | 0.0% |
| 2008 | -36.09 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -12.65 Thousand USD | -25.13% |
| 2024 Q4 | -7325.00 USD | 42.1% |
| 2024 Q2 | -10.11 Thousand USD | 79.61% |
| 2024 Q1 | -49.58 Thousand USD | -74.78% |
| 2023 Q3 | -81.86 Thousand USD | 24.82% |
| 2023 Q4 | -28.37 Thousand USD | 65.35% |
| 2023 Q1 | -234.93 Thousand USD | 9.72% |
| 2023 FY | -454.07 Thousand USD | 72.05% |
| 2023 Q2 | -108.89 Thousand USD | 53.65% |
| 2022 Q4 | -260.24 Thousand USD | 12.43% |
| 2022 Q3 | -297.17 Thousand USD | -118.1% |
| 2022 Q2 | 1.64 Million USD | 721.72% |
| 2022 FY | -1.62 Million USD | -88.59% |
| 2022 Q1 | -264.05 Thousand USD | -253.67% |
| 2021 Q4 | 171.83 Thousand USD | 174.83% |
| 2021 FY | -861.53 Thousand USD | 47.6% |
| 2021 Q3 | -229.63 Thousand USD | -104.04% |
| 2021 Q2 | 5.68 Million USD | 193.64% |
| 2021 Q1 | -6.07 Million USD | 0.0% |
| 2020 FY | -1.64 Million USD | -7402.03% |
| 2019 FY | -21.91 Thousand USD | -54.05% |
| 2018 FY | -14.22 Thousand USD | 96.19% |
| 2017 FY | -373.3 Thousand USD | -6342.49% |
| 2016 FY | 5980.00 USD | 0.0% |
| 2009 Q3 | -372.05 Thousand USD | -145.24% |
| 2009 Q2 | -151.71 Thousand USD | -1073.61% |
| 2009 Q1 | -12.92 Thousand USD | -106.89% |
| 2008 Q3 | -158.1 Thousand USD | -140.63% |
| 2008 Q2 | -65.7 Thousand USD | -410543.75% |
| 2008 FY | -36.09 Thousand USD | 0.0% |
| 2008 Q1 | -16.00 USD | 0.0% |
| 2008 Q4 | 187.72 Thousand USD | 218.74% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.15% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 87.401% |
| Nascent Biotech, Inc. | -2.08 Million USD | 96.184% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 80.823% |
| Qrons Inc. | -789.34 Thousand USD | 89.906% |
| Rebus Holdings, Inc. | -1.02 Million USD | 92.189% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.788% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.122% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.873% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 99.498% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 98.859% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 94.034% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.894% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 98.788% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 70.858% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.9% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 97.245% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 95.623% |
| Mesoblast Limited | -87.95 Million USD | 99.909% |
| Marizyme, Inc. | -65.34 Million USD | 99.878% |
| Genus plc | 7.9 Million USD | 101.009% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 99.268% |
| Pharming Group N.V. | -10.54 Million USD | 99.245% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 96.328% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 97.853% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 99.099% |
| ContraFect Corporation | -65.15 Million USD | 99.878% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 98.369% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 95.388% |
| IMV Inc. | -36.48 Million USD | 99.782% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 99.011% |
| MultiCell Technologies, Inc. | -380.07 USD | -20863.507% |
| ONE Bio Corp. | 8.67 Million USD | 100.918% |
| Accustem Sciences Inc. | -3.74 Million USD | 97.873% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.846% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 93.712% |
| Q BioMed Inc. | -2.05 Million USD | 96.117% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 97.866% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 96.653% |
| Biomind Labs Inc. | -1.21 Million USD | 93.439% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.867% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 97.431% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 98.992% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 95.912% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -432.025% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 98.63% |
| GB Sciences, Inc. | -1.36 Million USD | 94.149% |
| Alpha Cognition Inc. | -13.77 Million USD | 99.421% |
| HST Global, Inc. | -146.21 Thousand USD | 45.506% |
| CSL Limited | 2.64 Billion USD | 100.003% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 95.459% |
| Enzolytics Inc. | -2.17 Million USD | 96.34% |
| Agentix Corp. | -1.37 Million USD | 94.202% |
| Resverlogix Corp. | -3.61 Million USD | 97.793% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 97.488% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.973% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 181.302% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 101.151% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 97.995% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 97.367% |
| AVAX Technologies, Inc. | -6.41 Million USD | 98.758% |
| Zenith Capital Corp. | -10.59 Million USD | 99.248% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.917% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -242.81% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 98.078% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -31.825% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 96.026% |
| Kadimastem Ltd | -3.3 Million USD | 97.591% |
| Helix BioMedix, Inc. | -1.05 Million USD | 92.455% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 97.914% |
| BioStem Technologies, Inc. | -8.48 Million USD | 99.061% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 81.948% |
| LadRx Corporation | 400.44 Thousand USD | 119.897% |
| Cell Source, Inc. | -5.32 Million USD | 98.503% |
| Regen BioPharma, Inc. | 1.02 Million USD | 107.785% |
| Regen BioPharma, Inc. | 1.02 Million USD | 107.785% |
| NovAccess Global Inc. | -4.76 Million USD | 98.329% |
| Affymax, Inc. | -14.42 Million USD | 99.448% |
| Itoco Inc. | -1.86 Million USD | 95.737% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 98.207% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 95.226% |
| Mobile Lads Corp. | -2.26 Million USD | 96.48% |
| CytoDyn Inc. | -49.84 Million USD | 99.84% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -0.814% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 65.074% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 91.538% |
| SYBLEU INC | -180.3 Thousand USD | 55.81% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 95.06% |
| International Stem Cell Corporation | -131 Thousand USD | 39.179% |
| Bioxytran, Inc. | -4.28 Million USD | 98.138% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -46.809% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 96.851% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.834% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 96.231% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 89.797% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 97.485% |
| Neutra Corp. | -233.46 Thousand USD | 65.872% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 99.607% |
| PureTech Health plc | -65.69 Million USD | 99.879% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 99.625% |
| IXICO plc | -1.17 Million USD | 93.236% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 99.197% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.861% |
| CSL Limited | 2.64 Billion USD | 100.003% |
| Cellectis S.A. | -103.17 Million USD | 99.923% |